Cullinan Oncology (CGEM) Stock Forecast, Price Target & Predictions
CGEM Stock Forecast
Cullinan Oncology stock forecast is as follows: an average price target of $34.00 (represents a 193.10% upside from CGEM’s last price of $11.60) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
CGEM Price Target
The average price target for Cullinan Oncology (CGEM) is $34.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $30.00. This represents a potential 193.10% upside from CGEM's last price of $11.60.
CGEM Analyst Ratings
According to 6 Wall Street analysts, Cullinan Oncology's rating consensus is 'Buy'. The analyst rating breakdown for CGEM stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cullinan Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | David Dai | UBS | $30.00 | $15.61 | 92.18% | 158.62% |
| Aug 08, 2024 | Jeffrey Hung | Morgan Stanley | $38.00 | $16.38 | 131.99% | 227.59% |
| May 16, 2024 | Edward White | H.C. Wainwright | $28.00 | $26.72 | 4.79% | 141.38% |
| Apr 17, 2024 | Kaveri Pohlman | BTIG | $30.00 | $17.32 | 73.21% | 158.62% |
| Apr 16, 2024 | Edward White | H.C. Wainwright | $29.00 | $17.63 | 64.54% | 150.00% |
| Feb 03, 2023 | Morgan Stanley | $19.00 | $11.91 | 59.53% | 63.79% |
The latest Cullinan Oncology stock forecast, released on Oct 24, 2024 by David Dai from UBS, set a price target of $30.00, which represents a 92.18% increase from the stock price at the time of the forecast ($15.61), and a 158.62% increase from CGEM last price ($11.60).
Cullinan Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 5 |
| Avg Price Target | - | $30.00 | $31.00 |
| Last Closing Price | $11.60 | $11.60 | $11.60 |
| Upside/Downside | -100.00% | 158.62% | 167.24% |
In the current month, the average price target of Cullinan Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cullinan Oncology's last price of $11.60. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 29, 2024 | BTIG | Buy | Buy | Hold |
| Oct 24, 2024 | UBS | Buy | Initialise | |
| Oct 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 18, 2024 | BTIG | Buy | Buy | Hold |
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | William Blair | Outperform | Outperform | Hold |
| Aug 08, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| May 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 17, 2024 | BTIG | Buy | Buy | Hold |
| Apr 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 15, 2024 | William Blair | Outperform | Initialise | |
| Feb 03, 2023 | Morgan Stanley | Overweight | Overweight | Hold |
Cullinan Oncology's last stock rating was published by BTIG on Oct 29, 2024. The company gave CGEM a "Buy" rating, the same as its previous rate.
Cullinan Oncology Financial Forecast
Cullinan Oncology Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $18.94M | - |
| Avg Forecast | - | - | - | - | $746.35K | $2.09M | $2.05M | $1.93M | $15.00M | - | - | $275.00M | $18.92M | $9.00M |
| High Forecast | - | - | - | - | $746.35K | $2.09M | $2.05M | $1.93M | $15.00M | - | - | $275.00M | $18.92M | $9.00M |
| Low Forecast | - | - | - | - | $746.35K | $2.09M | $2.05M | $1.93M | $15.00M | - | - | $275.00M | $18.92M | $9.00M |
| # Analysts | - | - | - | - | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | - |
Cullinan Oncology's average Quarter revenue forecast for Jun 22 based on 1 analysts is $275.00M, with a low forecast of $275.00M, and a high forecast of $275.00M. CGEM's average Quarter revenue forecast represents a 1351.72% increase compared to the company's last Quarter revenue of $18.94M (Mar 21).
Cullinan Oncology EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-313.88M | $-55.00K | $-28.33M |
| Avg Forecast | - | - | - | - | $447.81K | $1.26M | $1.23M | $1.16M | $9.00M | - | - | $165.00M | $-100.18K | $5.40M |
| High Forecast | - | - | - | - | $447.81K | $1.26M | $1.23M | $1.16M | $9.00M | - | - | $165.00M | $-80.14K | $5.40M |
| Low Forecast | - | - | - | - | $447.81K | $1.26M | $1.23M | $1.16M | $9.00M | - | - | $165.00M | $-120.22K | $5.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | -1.90% | 0.55% | -5.25% |
undefined analysts predict CGEM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cullinan Oncology's previous annual EBITDA (undefined) of $NaN.
Cullinan Oncology Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $174.90M | $-70.00K | $-28.35M |
| Avg Forecast | $-42.69M | $-39.77M | $-37.01M | $-36.94M | $-46.47M | $-46.13M | $-45.88M | $-47.96M | $-46.34M | $-45.97M | $-39.92M | $298.20M | $-127.50K | $-21.20M |
| High Forecast | $-42.69M | $-39.77M | $-37.01M | $-36.94M | $-46.47M | $-46.13M | $-45.88M | $-41.11M | $-41.82M | $-45.97M | $-39.92M | $298.20M | $-102.00K | $-21.20M |
| Low Forecast | $-42.69M | $-39.77M | $-37.01M | $-36.94M | $-46.47M | $-46.13M | $-45.88M | $-57.66M | $-61.60M | $-45.97M | $-39.92M | $298.20M | $-153.00K | $-21.20M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.59% | 0.55% | 1.34% |
Cullinan Oncology's average Quarter net income forecast for Jun 24 is $-39.92M, with a range of $-39.92M to $-39.92M. CGEM's average Quarter net income forecast represents a -122.82% decrease compared to the company's last Quarter net income of $174.90M (Jun 22).
Cullinan Oncology SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $10.70M | $5.16M | $12.54M |
| Avg Forecast | - | - | - | - | $826.75K | $2.32M | $2.27M | $2.14M | $16.62M | - | - | $304.62M | $9.39M | $9.97M |
| High Forecast | - | - | - | - | $826.75K | $2.32M | $2.27M | $2.14M | $16.62M | - | - | $304.62M | $11.27M | $9.97M |
| Low Forecast | - | - | - | - | $826.75K | $2.32M | $2.27M | $2.14M | $16.62M | - | - | $304.62M | $7.51M | $9.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.04% | 0.55% | 1.26% |
Cullinan Oncology's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CGEM last annual SG&A of $10.70M (Jun 22).
Cullinan Oncology EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $3.90 | $-0.00 | $-0.68 |
| Avg Forecast | $-0.73 | $-0.68 | $-0.63 | $-0.63 | $-0.80 | $-0.79 | $-0.79 | $-0.82 | $-0.79 | $-0.79 | $-0.73 | $5.42 | $-0.12 | $-0.39 |
| High Forecast | $-0.73 | $-0.68 | $-0.63 | $-0.63 | $-0.80 | $-0.79 | $-0.79 | $-0.70 | $-0.72 | $-0.79 | $-0.73 | $5.42 | $-0.12 | $-0.39 |
| Low Forecast | $-0.73 | $-0.68 | $-0.63 | $-0.63 | $-0.80 | $-0.79 | $-0.79 | $-0.99 | $-1.06 | $-0.79 | $-0.73 | $5.42 | $-0.12 | $-0.39 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.72% | 0.01% | 1.75% |
According to 0 Wall Street analysts, Cullinan Oncology's projected average Quarter EPS for Jun 24 is $-0.73, with a low estimate of $-0.73 and a high estimate of $-0.73. This represents a -118.59% decrease compared to CGEM previous annual EPS of $3.90 (Jun 22).
Cullinan Oncology Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | $0.96 | $32.50 | 3285.42% | Buy |
| VOR | Vor Biopharma | $0.98 | $6.00 | 512.24% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| OLMA | Olema Pharmaceuticals | $6.14 | $27.00 | 339.74% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| SANA | Sana Bio | $1.91 | $8.00 | 318.85% | Buy |
| AUTL | Autolus Therapeutics | $2.49 | $7.60 | 205.22% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $3.13 | $7.00 | 123.64% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| BOLT | Bolt Biotherapeutics | $0.54 | $1.00 | 85.19% | Hold |
| LYEL | Lyell Immunopharma | $0.65 | $1.00 | 53.85% | Hold |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |